foscarnet has been researched along with EBV Infections in 9 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Herpes simplex virus (HSV) reactivations are usually prevented by acyclovir (ACV) prophylaxis, whereas cidofovir (CDV) has been used off indication to manage AdV infections." | 7.83 | Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation. ( Edelmann, A; Hofmann, J; Kühl, JS; Sauerbrei, A; Voigt, S, 2016) |
| "The lymphoproliferative disorders are usually treated with a combination of cytotoxic drugs, and virustatic medication is thought to be ineffective." | 5.31 | Regression of Epstein-Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet. ( Delecluse, HJ; Huhn, D; Ruhnke, M; Schneider, U; Stein, H, 2000) |
| " Herpes simplex virus (HSV) reactivations are usually prevented by acyclovir (ACV) prophylaxis, whereas cidofovir (CDV) has been used off indication to manage AdV infections." | 3.83 | Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation. ( Edelmann, A; Hofmann, J; Kühl, JS; Sauerbrei, A; Voigt, S, 2016) |
| "EBV retinitis was diagnosed based on EBV-positive (9." | 1.62 | Effects of intraocular treatments for Epstein-Barr virus (EBV) retinitis: A case report. ( Komoto, T; Mushiga, Y; Nagai, N; Ozawa, Y, 2021) |
| "Chronic active EBV infections (CAEBV) are often causative of malignant lymphoproliferative disorders, such as natural killer (NK) cell-lineage granular lymphocyte proliferative disorders (NK-GLPD), which are refractory to several conventional chemotherapies and usually show a poor prognosis." | 1.32 | Possibility of preventive treatment for EBV-associated NK cell-lineage proliferative disorders. ( Ishii, M; Ishii, T; Kawase, I; Kimura, H; Mori, KL; Morishima, T; Ohshima, S; Saeki, Y; Yamaguchi, N, 2003) |
| "Treatment with foscarnet, an inhibitor of viral-DNA polymerase, in three patients with EBV-associated post-transplant lymphoproliferative disease (PTLD) after heart (n = 2) and heart/kidney transplantation (n = 1), who did not respond to, or were not eligible for reduction of immunosuppression, resulted in complete remission (48+, 27 and 15 months respectively)." | 1.31 | Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease. ( Anagnostopoulos, I; Hummel, MW; Jonas, S; Oertel, SH; Riess, HB, 2002) |
| " Long-term administration (>1 year) of high-dose acyclovir or similar agents with anti-EBV activity may prevent NHL in patients with AIDS." | 1.31 | Value of long-term administration of acyclovir and similar agents for protecting against AIDS-related lymphoma: case-control and historical cohort studies. ( Fong, IW; Fong, MW; Ho, J; Lo, B; Toy, C, 2000) |
| "The lymphoproliferative disorders are usually treated with a combination of cytotoxic drugs, and virustatic medication is thought to be ineffective." | 1.31 | Regression of Epstein-Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet. ( Delecluse, HJ; Huhn, D; Ruhnke, M; Schneider, U; Stein, H, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Mushiga, Y | 1 |
| Komoto, T | 1 |
| Nagai, N | 1 |
| Ozawa, Y | 1 |
| Voigt, S | 1 |
| Hofmann, J | 1 |
| Edelmann, A | 1 |
| Sauerbrei, A | 1 |
| Kühl, JS | 1 |
| Oertel, SH | 1 |
| Anagnostopoulos, I | 1 |
| Hummel, MW | 1 |
| Jonas, S | 1 |
| Riess, HB | 1 |
| Ishii, M | 1 |
| Yamaguchi, N | 1 |
| Ohshima, S | 1 |
| Ishii, T | 1 |
| Mori, KL | 1 |
| Kimura, H | 1 |
| Morishima, T | 1 |
| Kawase, I | 1 |
| Saeki, Y | 1 |
| Tan, HH | 1 |
| Goh, CL | 1 |
| Zhang, SH | 1 |
| Zhou, XG | 1 |
| Yu, XM | 1 |
| Wang, C | 1 |
| Huang, SF | 1 |
| Fong, IW | 1 |
| Ho, J | 1 |
| Toy, C | 1 |
| Lo, B | 1 |
| Fong, MW | 1 |
| Schneider, U | 1 |
| Ruhnke, M | 1 |
| Delecluse, HJ | 1 |
| Stein, H | 1 |
| Huhn, D | 1 |
| Schramm, C | 1 |
| Schlaak, JF | 1 |
| Galle, PR | 1 |
1 review available for foscarnet and EBV Infections
| Article | Year |
|---|---|
Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Ad | 2006 |
8 other studies available for foscarnet and EBV Infections
| Article | Year |
|---|---|
Effects of intraocular treatments for Epstein-Barr virus (EBV) retinitis: A case report.
Topics: Adult; Epstein-Barr Virus Infections; Female; Foscarnet; Herpesvirus 4, Human; Humans; Methotrexate; | 2021 |
Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation.
Topics: Acyclovir; Adenoviridae; Adenovirus Infections, Human; Antibiotic Prophylaxis; Antiviral Agents; Chi | 2016 |
Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease.
Topics: Adult; Antiviral Agents; DNA-Binding Proteins; Epstein-Barr Virus Infections; Foscarnet; Gene Rearra | 2002 |
Possibility of preventive treatment for EBV-associated NK cell-lineage proliferative disorders.
Topics: Adolescent; Animals; Antiviral Agents; Cell Division; Chronic Disease; Culicidae; Epstein-Barr Virus | 2003 |
[Post-transplant lymphoproliferative disorders following allogenic bone marrow transplantation].
Topics: Adult; Antigens, CD20; Antiviral Agents; Bone Marrow Transplantation; CD3 Complex; Epstein-Barr Viru | 2005 |
Value of long-term administration of acyclovir and similar agents for protecting against AIDS-related lymphoma: case-control and historical cohort studies.
Topics: Acyclovir; Adult; Antiviral Agents; Case-Control Studies; Cohort Studies; Drug Therapy, Combination; | 2000 |
Regression of Epstein-Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Epstein-Barr Virus Infections; Foscarne | 2000 |
Rapid development of Epstein-Barr virus-associated Hodgkin's disease after cessation of foscarnet therapy in an HIV-infected patient.
Topics: Antiviral Agents; Epstein-Barr Virus Infections; Foscarnet; HIV Infections; Hodgkin Disease; Humans; | 2000 |